Day One Biopharmaceuticals
Day One Biopharmaceuticals is dedicated to developing targeted medicines for children and adults with serious diseases, aiming to bring life-changing therapies to patients faster. Founded in 2018, the company has achieved FDA approval for its first medicine, OJEMDA™, and is actively advancing its pipeline with innovative programs like Tovorafenib and DAY301. The company emphasizes a culture of collaboration, urgency, and integrity, working closely with patients, families, and partners to redefine hope from Day One.
Industries
Nr. of Employees
medium (51-250)
Day One Biopharmaceuticals
South San Francisco, California, United States, North America
Products
OJEMDA (tovorafenib)
An FDA‑approved, oral, brain‑penetrant type II RAF kinase inhibitor developed for treatment of certain pediatric low‑grade gliomas harboring activating RAF alterations.
DAY301 (PTK7-targeted ADC)
A clinical-stage PTK7-directed antibody–drug conjugate developed for adult and pediatric solid tumors; currently in Phase 1 dose-escalation and expansion studies.
OJEMDA (tovorafenib)
An FDA‑approved, oral, brain‑penetrant type II RAF kinase inhibitor developed for treatment of certain pediatric low‑grade gliomas harboring activating RAF alterations.
DAY301 (PTK7-targeted ADC)
A clinical-stage PTK7-directed antibody–drug conjugate developed for adult and pediatric solid tumors; currently in Phase 1 dose-escalation and expansion studies.
Services
Strategic partnering and licensing
Collaborative partnerships for identification, acquisition, and co‑development or licensing of therapeutic programs, including external licensing and global commercialization agreements.
Investigator‑sponsored trial support
Consideration of support for investigator-initiated clinical studies via provision of investigational drug, funding, or other collaboration under formal agreements.
Patient access and support program
Personalized services to support patients receiving approved therapy including insurance coverage assistance, financial assistance options, home delivery of medication, and patient navigation.
Strategic partnering and licensing
Collaborative partnerships for identification, acquisition, and co‑development or licensing of therapeutic programs, including external licensing and global commercialization agreements.
Investigator‑sponsored trial support
Consideration of support for investigator-initiated clinical studies via provision of investigational drug, funding, or other collaboration under formal agreements.
Patient access and support program
Personalized services to support patients receiving approved therapy including insurance coverage assistance, financial assistance options, home delivery of medication, and patient navigation.
Expertise Areas
- Clinical trial management
- Oncology drug development
- Antibody–drug conjugates (ADC) development
- Small-molecule kinase inhibitor development
Key Technologies
- Antibody–drug conjugates (ADC)
- Small-molecule kinase inhibitors
- Preclinical tumor models (in vivo efficacy)
- Biomarker-driven patient selection (genomic alterations)